Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

Abstract Background The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Pl...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Francisco Martínez-Dubarbie, Armando Guerra-Ruiz, Sara López-García, Carmen Lage, Marta Fernández-Matarrubia, Jon Infante, Ana Pozueta-Cantudo, María García-Martínez, Andrea Corrales-Pardo, María Bravo, Marcos López-Hoyos, Juan Irure-Ventura, Pascual Sánchez-Juan, María Teresa García-Unzueta, Eloy Rodríguez-Rodríguez
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2023-10-01
Серія:	Alzheimer’s Research & Therapy
Предмети:	Alzheimer’s disease Plasma biomarkers Early diagnosis Screening Validation Lumipulse
Онлайн доступ:	https://doi.org/10.1186/s13195-023-01319-1
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

Схожі ресурси